Elsevier

Biochemical Pharmacology

Volume 39, Issue 11, 1 June 1990, Pages 1743-1750
Biochemical Pharmacology

Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages

https://doi.org/10.1016/0006-2952(90)90120-AGet rights and content

Abstract

Low density lipoproteins (LDL) can be oxidatively modified in vitro by macrophages and certain other cell types so that macrophages will take them up much faster. This process may be important in the formation of cholesterol-laden foam cells derived from macrophages in atherosclerotic lesions. In this study, we have shown that certain flavonoids, plant constituents found in the diet, are potent inhibitors of the modification of 125I-labelled LDL by macrophages, with ic50 values in the micromolar range (e.g. morin and fisetin 1 μM; quercetin and gossypetin 2 μM). The potencies of individual flavonoids in inhibiting LDL modification did not correlate with their previously determined potencies as inhibitors of 5-lipoxygenase and cyclo-oxygenase. The modification of LDL by macrophages exhibits a lag period of about 4–6 hr before enhanced uptake is detected. During this time, there is a rapid depletion in its content of α-tocopherol (an endogenous antioxidant found in lipoproteins) followed by a large increase in the level of hydroperoxides. The flavonoids conserved the α-tocopherol content of LDL and delayed the onset of detectable lipid peroxidation. Flavonoids also inhibited the cell-free oxidation of LDL mediated by CuSO4. These findings raise the possibility that flavonoids may protect LDL against oxidation in atherosclerotic lesions and may therefore be natural anti-atherosclerotic components of the diet, although this will depend to a large extent on their pharmacokinetics.

References (53)

  • GR Schacterle et al.

    The simplified method for the quantitative assay of small amounts of protein in biologic material

    Anal Biochem

    (1973)
  • CA Drevon et al.

    Metabolism of homologous and heterologous lipo-proteins by cultured rat and human skin fibroblasts

    J Lipid Res

    (1981)
  • SM Thomas et al.

    A continuous-flow automated assay for iodometric estimations of hydroperoxides

    Anal Biochem

    (1989)
  • AI Tauber et al.

    Flavonoid inhibition of the human neutrophil NADPH-oxidase

    Biochem Pharmacol

    (1984)
  • E Niki

    Antioxidants in relation to lipid peroxidation

    Chem Phys Lipids

    (1987)
  • M Thompson et al.

    Stability of flavonoid complexes of copper (II) and flavonoid antioxidant activity

    Analytica Chim Acta

    (1976)
  • NP Das

    Studies on flavonoid metabolism: absorption and metabolism of(+)-catechin in man

    Biochem Pharmacol

    (1971)
  • MS Brown et al.

    Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis

    Annu Rev Biochem

    (1983)
  • T Henriksen et al.

    Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoprotein

  • T Henriksen et al.

    Enhanced macrophage degradation of biologically modified low density lipoprotein

    Arteriosclerosis

    (1983)
  • S Parthasarathy et al.

    Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor

    Arteriosclerosis

    (1986)
  • SM Rankin et al.

    The modification of low-density lipoproteins by macrophages in relation to atherosclerosis

    Biochem Soc Trans

    (1987)
  • SM Rankin et al.

    The modification of low-density lipoproteins by macrophages by oxidation or proteolysis

    Agent Action Suppl

    (1988)
  • W Jessup et al.

    α-Tocopherol consumption during low-density-lipoprotein oxidation

    Biochem J

    (1990)
  • ME Haberland et al.

    Malondi-aldehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits

    Science

    (1988)
  • IN Trakht et al.

    Investigation of human blood plasma apoB- containing lipo-proteins by means of monoclonal antibodies against low density lipoproteins

  • Cited by (0)

    Present address: Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, U.S.A.

    Present address: Heart Research Institute, Sydney, N.S.W. 2050, Australia.

    View full text